Non-viral gene therapy for diabetic retinopathy

Delivery systems and local administration routes for therapeutic siRNA

With the increasing number of studies proposing new and optimal delivery strategies for the efficacious silencing of gene-related diseases by the local administration of siRNAs, the present review aims to provide a broad overview of the most important and latest developments of non-viral siRNA delivery systems for local administration. Moreover, the main disease targets for the local delivery of siRNA to specific tissues or organs, including the skin, the lung, the eye, the nervous system, the digestive system and the vagina, were explored.

Illuminating the gateway of gene silencing: perspective of RNA interference technology in clinical therapeutics

A novel laboratory revolution for disease therapy, the RNA interference (RNAi) technology, has adopted a new era of molecular research as the next generation "Gene-targeted prophylaxis." In this review, we have focused on the chief technological challenges associated with the efforts to develop RNAi-based therapeutics that may guide the biomedical researchers. Many non-curable maladies, like neurodegenerative diseases and cancers have effectively been cured using this technology. Rapid advances are still in progress for the development of RNAi-based technologies that will be having a major impact on medical research. We have highlighted the recent discoveries associated with the phenomenon of RNAi, expression of silencing molecules in mammals along with the vector systems used for disease therapeutics.

Changes of macular and RNFL thicknesses measured by Stratus OCT in patients with early stage diabetes

PURPOSE

To examine the early differences in the thicknesses of the macula and retinal nerve fibre layer (RNFL) by Stratus optical coherence tomography in patients with diabetes mellitus.

METHODS

Thirty-one normal participants without any optic nerve and retinal diseases (control), 45 diabetic patients without diabetic retinopathy (NDR), and 24 diabetic patients with preproliferative diabetic retinopathy (PPDR), who did not have clinically significant macular oedema, were used for the macular thickness measurements. Thirty control participants, 45 patients classified as NDR, and 22 patients classified as PPDR were used for the RNFL thickness measurements.

RESULTS

In patients with NDR, macula was significantly thinner than that of control eyes. In patients with PPDR, the mean RNFL thickness was significantly thinner but the macula was thicker than that of control eyes. In women with NDR, the macula was significantly thinner than that of men with NDR and that of normal women. In men with PPDR, the RNFL thickness was significantly thinner than that of the control eyes.

CONCLUSIONS

At the early stage of diabetic retinopathy, the maculas and RNFL thicknesses are altered. The macular and RNFL thicknesses are different in men and women.